Customize your JAMA Network experience by selecting one or more topics from the list below.
Tapper EB, Sengupta N, Lai M, Horowitz G. A Decision Support Tool to Reduce Overtesting for Ceruloplasmin and Improve Adherence With Clinical Guidelines. JAMA Intern Med. 2015;175(9):1561–1562. doi:10.1001/jamainternmed.2015.2062
Nondirected testing, simultaneously assessing a multitude of diseases, is a specific form of overtesting. This pattern of testing is expensive and generates false-positive test results.1 It is also common, particularly for the evaluation of liver disease.2,3 For example, elevated liver enzymes affect 7.9% of the US population, whereas Wilson disease, an inborn error of copper metabolism associated with liver injury, is routinely assessed along with viral hepatitis despite affecting only 0.003% of the US population.3-5
Guidelines suggest testing for Wilson disease with ceruloplasmin blood levels after excluding common liver diseases and, given the rarity of late-onset Wilson disease, recommends rarely testing patients older than 55 years.4 We conducted a prospective study to evaluate the effect of a decision support tool on ceruloplasmin use by measuring use rates 7 months before and 7 months after implementing an electronic pop-up in electronic medical record system at Beth Israel Deaconess Medical Center. The study reviewed records from October 1, 2013, through November 27, 2014.
Create a personal account or sign in to: